- Home
- NPKI vs ABUS Comparison
NPKI vs ABUS Comparison
Compare NPKI & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- ABUS
- Stock Information
- Founded
- NPKI 1932
- ABUS N/A
- Country
- NPKI United States
- ABUS United States
- Employees
- NPKI N/A
- ABUS N/A
- Industry
- NPKI Metal Fabrications
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- NPKI Industrials
- ABUS Health Care
- Exchange
- NPKI Nasdaq
- ABUS Nasdaq
- Market Cap
- NPKI 621.1M
- ABUS 629.1M
- IPO Year
- NPKI N/A
- ABUS N/A
- Fundamental
- Price
- NPKI $7.01
- ABUS $3.40
- Analyst Decision
- NPKI
- ABUS Strong Buy
- Analyst Count
- NPKI 0
- ABUS 4
- Target Price
- NPKI N/A
- ABUS $5.50
- AVG Volume (30 Days)
- NPKI 385.2K
- ABUS 696.1K
- Earning Date
- NPKI 02-19-2025
- ABUS 02-27-2025
- Dividend Yield
- NPKI N/A
- ABUS N/A
- EPS Growth
- NPKI N/A
- ABUS N/A
- EPS
- NPKI N/A
- ABUS N/A
- Revenue
- NPKI $748,372,000.00
- ABUS $6,742,000.00
- Revenue This Year
- NPKI N/A
- ABUS N/A
- Revenue Next Year
- NPKI N/A
- ABUS N/A
- P/E Ratio
- NPKI N/A
- ABUS N/A
- Revenue Growth
- NPKI 93.70
- ABUS N/A
- 52 Week Low
- NPKI $5.61
- ABUS $2.30
- 52 Week High
- NPKI $8.65
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- NPKI N/A
- ABUS 53.80
- Support Level
- NPKI N/A
- ABUS $3.17
- Resistance Level
- NPKI N/A
- ABUS $3.45
- Average True Range (ATR)
- NPKI 0.00
- ABUS 0.11
- MACD
- NPKI 0.00
- ABUS 0.02
- Stochastic Oscillator
- NPKI 0.00
- ABUS 82.76
About NPKI NPK International Inc. Common Stock
NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.